Literature DB >> 21115880

Delayed neoplastic and renal complications in women receiving long-term chemotherapy for recurrent ovarian cancer.

Franco Muggia, Timothy Cannon, Tamar Safra, John Curtin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21115880     DOI： 10.1093/jnci/djq484

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  7 in total

Review 1.  Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.

Authors:  Sean T Duggan; Gillian M Keating
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  Squamous cell carcinoma of the oral tongue in two patients previously exposed to long-term pegylated liposomal doxorubicin.

Authors:  Marcelo R Bonomi; Krzysztof Misiukiewicz; Marshall Posner; Robert G Maki
Journal:  Oncologist       Date:  2012-05-23

3.  Squamous cell carcinomas of the tongue and oral cavity as secondary malignancies: what factors are implicated?

Authors:  Franco Muggia
Journal:  Oncologist       Date:  2013-03-13

4.  Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?

Authors:  Maryann Kwa; Robert Baumgartner; Linda Shavit; Irina Barash; Jeffrey Michael; Igor Puzanov; Juri Kopolovic; Ora Rosengarten; Stephanie Blank; John P Curtin; Alberto Gabizon; Franco Muggia
Journal:  Oncologist       Date:  2012-05-23

5.  Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer?

Authors:  Timothy L Cannon; Dominic W Lai; David Hirsch; Mark Delacure; Andrea Downey; Alexander R Kerr; Michael Bannan; Eleni Andreopoulou; Tamar Safra; Franco Muggia
Journal:  Oncologist       Date:  2012-05-23

Review 6.  Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics.

Authors:  Sarah A Engelberth; Nadine Hempel; Magnus Bergkvist
Journal:  Crit Rev Oncog       Date:  2014

7.  Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.

Authors:  Bhavana Pothuri; Allison L Brodsky; Joseph A Sparano; Stephanie V Blank; Mimi Kim; Dawn L Hershman; Amy Tiersten; Brian F Kiesel; Jan H Beumer; Leonard Liebes; Franco Muggia
Journal:  Cancer Chemother Pharmacol       Date:  2020-02-13       Impact factor: 3.333
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.